Analysis Of Income And Expense [Abstract]

Hyloris Pharmaceuticals SA - Filing #3166293

Concept	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue	—	—	—	—	3,096 EUR	—	—	—	175,000 EUR	—	—
Material income and expense [abstract]
Research and development expense	—	—	—	—	5,056 EUR	—	—	—	3,413 EUR	—	—
Miscellaneous other operating income	—	—	—	—	389,000 EUR	—	—	—	21,000 EUR	—	—
Miscellaneous other operating expense	—	—	—	—	5,770 EUR	—	—	—	- EUR	—	—
Selling, general and administrative expense [abstract]
General and administrative expense	—	—	—	—	2,900 EUR	—	—	—	2,194 EUR	—	—
Share of profit (loss) of associates and joint ventures accounted for using equity method [abstract]
Share of profit (loss) of associates and joint ventures accounted for using equity method	—	—	—	—	191,000 EUR	—	—	—	—	—	—
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	11,579 EUR	- EUR	- EUR	- EUR	11,579 EUR	- EUR	7,145 EUR	- EUR	7,145 EUR	- EUR	- EUR
Comprehensive income attributable to owners of parent, continuing and discontinued operations [abstract]
Comprehensive income, attributable to owners of parent	—	—	—	—	11,579 EUR	—	—	—	7,145 EUR	—	—
Comprehensive income attributable to non-controlling interests, continuing and discontinued operations [abstract]
Comprehensive income, attributable to non-controlling interests	—	—	—	—	—	—	—	—	- EUR	—	—